How To Identify A Compound’s ADME Properties With Innovative In Vitro ADME Screening?

The initial stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the success of a drug candidate. A key reason for the high rate of failure of drugs in clinical trials is attributed to problems related to their pharmacokinetic profiles and ADME properties. Therefore, The ADME (Absorption, Distribution, Metabolism, and Elimination) properties of a drug candidate and its potential for drug interactions is best determined early when running a drug discovery program. Identifying ADME parameters early helps to de-risk candidate molecules and enhance project productivity through more targeted chemical synthesis and progression of compounds.

When done correctly, ADME assays can be used to describe the potential impact a drug may have on a living system within the context of cellular biology and biochemistry. Early ADME screens combined with toxicity studies provide accurate information of the metabolism and safety profile of a drug candidate giving researchers important information on a drug candidate's likelihood of success in the clinic. In the past, researchers mainly relied on animal studies to know these predictions. However now, primary cells derived from human tissue are used in many cases as alternatives to animal models. It is important to conduct these studies in a highly controlled environment, which is why researchers depend on their deep industry knowledge and FDA recommended standards for the In Vitro ADME studies.

Choosing a Contract Research Organization (CRO) to Perform In Vitro ADME/PK Screenings

In vitro ADME/PK screening minimizes failure rates later on by giving the right information on ADME and potential drug-drug interactions (DDIs).

To assist you in your drug discovery program, IONTOX offers the following in vitro ADME studies: Caco-2 Permeability, Metabolic Stability, CYP Induction, CYP Inhibition, Plasma Protein Binding, Blood Partitioning, and Evaluation of Transporter Interactions.

To learn more about the In vitro ADME offerings from IONTOX, visit https://www.iontox.com/in-vitro-adme-pk-testing/ today.

IONTOX is a biotechnology company founded in 2014 dedicated to providing expertise to the area of in vitro toxicology, with a mission to build improved methods for predicting human adverse effects from chemical..